101. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.
- Author
-
Tracy TE, Madero-Pérez J, Swaney DL, Chang TS, Moritz M, Konrad C, Ward ME, Stevenson E, Hüttenhain R, Kauwe G, Mercedes M, Sweetland-Martin L, Chen X, Mok SA, Wong MY, Telpoukhovskaia M, Min SW, Wang C, Sohn PD, Martin J, Zhou Y, Luo W, Trojanowski JQ, Lee VMY, Gong S, Manfredi G, Coppola G, Krogan NJ, Geschwind DH, and Gan L
- Subjects
- Alzheimer Disease genetics, Amino Acids metabolism, Biotinylation, Brain metabolism, Brain pathology, Cell Nucleus metabolism, Disease Progression, Energy Metabolism, Frontotemporal Dementia genetics, Humans, Induced Pluripotent Stem Cells metabolism, Mutant Proteins metabolism, Mutation genetics, Nerve Degeneration pathology, Neurons metabolism, Protein Binding, Protein Domains, Proteomics, Severity of Illness Index, Subcellular Fractions metabolism, Tauopathies genetics, tau Proteins chemistry, Mitochondria metabolism, Nerve Degeneration metabolism, Protein Interaction Maps, Synapses metabolism, tau Proteins metabolism
- Abstract
Tau (MAPT) drives neuronal dysfunction in Alzheimer disease (AD) and other tauopathies. To dissect the underlying mechanisms, we combined an engineered ascorbic acid peroxidase (APEX) approach with quantitative affinity purification mass spectrometry (AP-MS) followed by proximity ligation assay (PLA) to characterize Tau interactomes modified by neuronal activity and mutations that cause frontotemporal dementia (FTD) in human induced pluripotent stem cell (iPSC)-derived neurons. We established interactions of Tau with presynaptic vesicle proteins during activity-dependent Tau secretion and mapped the Tau-binding sites to the cytosolic domains of integral synaptic vesicle proteins. We showed that FTD mutations impair bioenergetics and markedly diminished Tau's interaction with mitochondria proteins, which were downregulated in AD brains of multiple cohorts and correlated with disease severity. These multimodal and dynamic Tau interactomes with exquisite spatial resolution shed light on Tau's role in neuronal function and disease and highlight potential therapeutic targets to block Tau-mediated pathogenesis., Competing Interests: Declaration of interests L.G. is a founder of Aeton Therapeutics. N.J.K. received research support from Vir Biotechnology and F. Hoffmann-La Roche; has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, and Interline Therapeutics; is a shareholder in Tenaya Therapeutics, Maze Therapeutics, and Interline Therapeutics; and is a financially compensated Scientific Advisory Board Member for GEn1E Life sciences., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF